anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Pulmonary benign metastasizing leiomyoma is an uncommon condition, predominantly affecting women of childbearing age with a history of uterine smooth muscle tumors and uterine leiomyoma surgery for uterine leiomyoma. The progression of PBML is often unpredictable and depends on the extent of lung involvement. Generally, most patients remain asymptomatic, but a minority may experience coughing, wheezing, or shortness of breath, which are frequently misdiagnosed as pneumonia. consequently, this presents significant challenges in both treatment and nursing care before diagnosis. This paper reports the case of a 35-year-old woman primarily diagnosed with acute hypoxic respiratory failure who was transferred from the emergency room to the intensive care unit. The initial computed tomography scan of the patient's lungs indicated diffuse interstitial pneumonia, but the sequencing of the alveolar lavage fluid pathogen macro did not detect any bacteria, fungi, or viruses. Moreover, the patient remained in a persistent hypoxic state before the definitive diagnosis. Therefore, our focus was on maintaining the airway patency of the patient, using prone ventilation, inhaling nitric oxide, monitoring electrical impedance tomography, and preventing ventilator-associated pneumonia to improve oxygenation, while awaiting immunohistochemical staining of the patient's biopsied lung tissue. This would help us clarify the diagnosis and treat it based on etiology. After meticulous treatment and nursing care, the patient was weaned off the ventilator after 26 days and transferred to the respiratory ward after 40 days. This case study may serve as a reference for clinical practice and assist patients suffering from PBML.
Patients receive \[18F\]-DCFPyL IV and undergo \[18F\]-DCFPyL PET-CT over 30 minutes per SOC. Patients with PET avid lesions then undergo a X1 RMRS PET-CT imaging-only session within 120 minutes of injection over 20-35 minutes.
The invention discloses sulfur-containing diindolyl diketopiperazine compounds and application thereof in preparing antineoplastic drugs. Five sulfur-containing diindolyl diketopiperazine compounds are separated from the marine eumycete Acrostalagmus luteoalbus SCSIO F457. The structural formula is disclosed as Formula (I). The compounds 1-5 have strong growth inhibition action on human central nervous system cancer cell SF-268, human breast cancer cell MCF-7, human large-cell lung cancer cell NCI-H460 and human liver cancer cell HepG2, have better effects than the positive control drug cisplatin on the whole, and can be used for preparing antineoplastic drugs. Therefore, the invention provides alternate compounds for developing new antineoplastic drugs, and has important meanings for developing Chinese marine drug resources. The formula (I) is shown in the description.
Control group participants will complete surveys on a tablet during the postpartum hospital stay. Surveys cover three topic areas related to breast-feeding; modeling and feedback, partner support, and stress coping. The control group participants will be sent 4 text messages per week for the first 6 weeks, but the content of the texts will be non-breastfeeding related. The content will instead summarize infant development facts.
PURPOSE:To obtain a fat emulsion containing superoxide dismutase bonded lipid microspheres. CONSTITUTION:Superoxide dismutase is externally bonded to the surface of lipid microspheres [consisting of fats and oils (vegetable oil, triglyceride of 8-12C middle chain fatty acid or di- or mono-glyceride of 6-18C fatty acid) and an emulsifying agent (phospholipid or nonionic surface active agent)] and both the components are bonded by crosslinking bond through -S- or -SS- covalent bond to give superoxide dismutase bonded lipid microspheres. The microspheres are optionally blended with additives such as an emulsion auxiliary (e.g. stearic acid) and a stabilizer (e.g. cholesterol or tocopherol), heated into a solution and processed by a means such as homogenizer to give a fat emulsion. The emulsion has <=0.5mu average particle diameter.
Study population: The study will include adults admitted to Internal Medicine B (IMB) department, Internal Medicine H (IMH) department or medical intensive care unit (MICU) in Rambam-Health Care Campus for moderate to severe Asthma exacerbation. The severity of the exacerbation will be based on several acceptable clinical and laboratory criteria, including breathless, alertness, pulse rate, respiratory rate, partial pressure of oxygen in arterial blood (PaO2), partial pressure of carbon dioxide in arterial blood (PaCO2), oxygen saturation, peak expiratory flow (PEF). Study protocol: The study is a prospective, randomized, double-blind, placebo-controlled, clinical trial. Patients will be randomized on admission to receive treatment with intra-venous thyroxine (100mcg once on admission and additional 100mcg after 12 hours) or placebo. The study treatment will be given only after the initial bronchodilator therapy, oxygen and informed consent are given. The primary endpoint is the time to return of the PEF rate to normal values or personal base line. PEF rates will be examined first after initial bronchodilator therapy and then, every 8 hours.
Nucleotide-binding domain and leucine-rich repeat (NLR) proteins can engage in complex interactions to detect pathogens and execute a robust immune response via downstream helper NLRs. However, the biochemical mechanisms of helper NLR activation by upstream sensor NLRs remain poorly understood. Here, we show that the coiled-coil helper NLR NRC2 from Nicotiana benthamiana accumulates in vivo as a homodimer that converts into a higher-order oligomer upon activation by its upstream virus disease resistance protein Rx. The cryo-EM structure of NbNRC2 in its resting state revealed intermolecular interactions that mediate homodimer formation and contribute to immune receptor autoinhibition. These dimerization interfaces have diverged between paralogous NRC proteins to insulate critical network nodes and enable redundant immune pathways, possibly to minimise undesired cross-activation and evade pathogen suppression of immunity. Our results expand the molecular mechanisms of NLR activation pointing to transition from homodimers to higher-order oligomeric resistosomes.
For each choir session, the choir director will be supported by an accompanist who will provide the music accompaniment for the songs and four section leaders who will provide musical leadership for choral sections (soprano, alto tenor \& bass). At the beginning of each choir group, participants will be asked about their favorite songs to help ensure that the music will be appropriate for the participants' interest and cultural background. Each choir group will rehearse once a week for two hours with a short break in the middle for snacks for a total of 16 consecutive weeks. The choir rehearsals will follow a general routine, beginning with announcements and warm-ups, work on the repertoire, a break, additional work on the repertoire in sections, and a short group practice at the end. Participants will also be given at-home activities, in the form of pre-recorded videos and music theory exercises to complete outside of class for an estimated 1.5 hours per week.
Personalization of access to health-related information on a computer network is provided based upon a health history of a user. In one implementation, personal health-related information about the user is obtaining from the user operating a client computer. The health-related information includes one or more health-related terms that each corresponds to a health-related concept. The health related terms provided by the user are correlated with a health terminology thesaurus that is stored on a computer-readable medium, such as at a server remote from the user client. Each of the health-related terms is associated with a single concept unique identifier that uniquely identifies a corresponding health-related concept. Health-related works or content is made accessible over the computer network by correlating the concept unique identifiers for the user's health information with corresponding concept unique identifiers that are associated with the health-related content.
The experimental group will receive ACZ at a daily dose of 600 mg, equivalent to 100mg of elemental zinc (one hard gelatin capsule of 300 mg of ACZ twice a day). Treatment will be stopped when the patient presents any of the events that define the main endpoint of the study.
OBJECTIVE: Spinal involvement in rheumatoid arthritis (RA) is limited to the upper cervical spine, leading to cervical spine instability. This study aimed to evaluate the prevalence of anterior atlantoaxial subluxation (aAAS) and its associated risk factors in patients with RA.
METHOD: This single-centre cross-sectional study 240 patients consecutively were recruited. Radiographs of the cervical spine were obtained in the flexion and neutral neck positions and read by two blinded observers. The diagnosis of aAAS was based on the distance between the anterior aspect of the dens and the posterior aspect of the anterior arch of the atlas, which was >3 mm during flexion. Statistical analysis was performed to determine the predictive factors of aAAS.
RESULTS: Two hundred and forty patients with a mean ± SD age of 56.4 ± 11.4 years were recruited, and 191 (78%) were female. The mean ± SD duration of the disease was 10.2 ± 8.5 years. Of all 25 cases (10.4%) diagnosed with aAAS, the mean anterior atlantodental interval in patients with AAS was 4.19 ± 1.20 mm. One in three patients with aAAS had no neck pain. Patients with aAAS had longer disease duration, lower age at diagnosis, lower body mass index, higher anti-cyclic citrullinated peptide autoantibodies (anti-CCP), more frequent erosion, joint restriction, and joint prostheses. In the multivariate regression model, joint limitation, history of joint prostheses, low BMI, and higher anti-CCP levels were independent predictors of the aAAS.
CONCLUSION: Thirty-three percent of patients with cervical involvement do not experience neck pain. Cervical involvement should be considered even without neck pain, particularly in established diseases.
PURPOSE:To obtain a bathing agent, containing drug effective ingredients of Howttuynia cordata Thunb. with hardly feeling of peculiar unpleasant smell by heat-treating a green juice of Howttuynia cordata Thunb., then subjecting the heat-treated green juice to oxidation treatment, subsequently initiating alcoholic fermentation, collecting precipitates from the fermented liquor and drying the collected precipitates. CONSTITUTION:A green juice of Howttuynia cordata Thunb. is heat-treated at 70-80 deg.C temperature for about 10-30min and sterilized and most of lauric aldehyde, capric aldehyde, etc., which are malodorous ingredients are simultaneously oxidized and evaporated. After the heat treatment, oxygen gas or an oxidizing agent or both are used together to carry out oxidation treatment, completely decompose malodorous ingredients remaining without being removed by the heat treatment and deodorize the juice. A saccharide and an alcoholic fermentation yeast are subsequently added to initiate alcoholic fermentation. After completing the fermentation, the fermentation liquor is filtered to collect precipitates, which are then preferably dried by a freeze-drying method. After completing the fermentation, a supernatant liquid separated from the precipitates can be utilized as an alcoholic beverage.
FIELD: medicine, oncourology. SUBSTANCE: in patients one should detect the content of interleukin-6, acid-labile fraction of interferon- alpha/beta, interferongamma, CD 8, CD 25, CD 95. If the content of interleukin-6 and/or acid-labile fraction of interferonalpha/beta is 1.5 times higher and more against the norm and/or the content of interferon-gamma is 3 times higher and more against the norm patient is prescribed to undergo immunochemotherapy. If the content of interleukin-6 and acid-labile fraction of interferon-alpha/beta is not more than 1.5 times higher against the norm, the content of interferon-gamma is not more than 3 times higher against the norm, the content of CD 25 is in norm or higher, the content of CD 8 is below and/or the content of CD 95 is above the norm one should daily intravenously inject Rhoncoleukin for the patient for 2 wk by alternating 0.5 and 1.0 mg dosages/injection. If the content of CD 25 is below the norm patient is subcutaneously preinjected with Rhoncolekin for 5 d. If, under these conditions CD 8 is above and CD 95 is below the norm at no signs of clinical progressing one should temporary stop therapy to perform dynamic inspection for the patient. Then therapeutic tactics is carried out many times in accordance with immunogram by repeating it every three months. Immunochemotherapy is necessary to be conducted due to intravenous injection of 5-fluorouracil and Rhoncoleukin by alternating with interferon-alpha in certain modes and dosages. The present method provides individual character of therapy and its adequacy, enables to improve results of therapy in patients with removed metastasis. EFFECT: higher efficiency. 1 cl, 2 tbl
The invention provides an Avian Encephalomyelitis virus YBF02 strain. The strain, with a preservation number of CGMCC (China General Microbiological Culture Collection Center) No. 8505, is preserved in China General Microbiological Culture Collection Center on November 8, 2013 at No. 3, Yard No. 1, Beichen West Road, Chaoyang District, Beijing. The Avian Encephalomyelitis virus attenuated vaccine strain screened according the invention is subjected to continuous passage in a chicken body by horizontal transmitted infection, and no virulence return phenomenon occurs, therefore, the strain is stable in hereditary, and accords with the standard of no virulence return of Avian Encephalomyelitis virus attenuated vaccine strains; prepared vaccines can provide effective immune protection, and have a good commercial development prospect.
Two methods are recommended for the identification of fetal movements. These are the Cardiff method and the Sadovsky method. In the assessment of fetal health, not only the number of movements per unit of time is important, but also the strength and nature of these movements. To take this into account, in 2012 Radestad introduced another method of observing the character of the movement, called "Mindfetalness". The method is based on women who develop maternal awareness of the health of the foetus and note the quality of the perceived movements. The method requires the mother to lie on her left side while her baby is awake and focus for 15 minutes on exactly how the baby is moving, taking into account the strength, type and frequency of movement. However, the number of fetal movements is not counted during this time period. This method, which helps women to note fetal movements in order to minimise and/or eliminate adverse birth outcomes, is also reported to cause unnecessary stress to the mother, as with other methods.Although there are studies reporting that counting fetal movements contributes to maternal attachment by increasing the possibility of connecting with the unborn baby, there are also studies that found no difference in maternal-fetal attachment scores. However, it is thought that focusing on the quality rather than the quantity of movements will increase the opportunity to connect with the fetus.

There is no previous comparison in the literature between a self-assessment method that focuses on qualitative variables and a counting method to measure fetal movements. Although there is one study that used both methods, this study did not differentiate between experimental and control groups, but used the crossover method and tested both methods on the same pregnant women. Therefore, our study was planned to determine the effect of fetal movement counting with two different self-assessment methods on prenatal attachment and psychosocial status.
FIELD: veterinary science, virology. SUBSTANCE: invention relates to preparing prophylactic preparations against Newcastle disease in poultry. Granulated vaccine has lactose, chicken embryos allantois liquid containing vaccine strain "La-Sota" of Newcastle disease virus of poultry, peptone and starch. Vaccine retains activity without any change for 6 months at 4 C and for 2 weeks at 25 C. Expressing immunity in vaccinated poultry is 100% after a single vaccination. EFFECT: increased thermostability and immunogenicity of granulated lactose-containing vaccine against Newcastle disease in poultry for oral use. 2 tbl
PCT No. PCT/GB94/00669 Sec. 371 Date Aug. 21, 1995 Sec. 102(e) Date Aug. 21, 1995 PCT Filed Mar. 30, 1994 PCT Pub. No. WO94/22483 PCT Pub. Date Oct. 13, 1994The invention relates to a pharmaceutically acceptable prodrug which is a covalent conjugate of a pharmacologically active compound and an intracellular transporting adjuvant, characterized by the presence of a covalent bond which is scission-sensitive to intracellular enzyme activity. The prodrug may be used in a technique for treating a condition or disease in a human related to supranormal intracellular enzyme (.e.g. phospholipase and/or esterase) activity, whereby on administering it to a human having such condition or disease, the bond is broken in response to such activity, and the pharmacologically active compound accumulates selectively within cells having such supranormal intracellular enzyme activity. Exemplary conjugates are esters of the carboxylic function in the formula, with e.g. heptanoyl-sn-3-glycerophosphoryl-choline or octanoyl-sn-3-glycerophosphoryl-choline.
This is a Phase 0 multi-center and longitudinal study of biomarkers and clinical parameters in patients with lupus erythematosus (LE). Approximately 80 participants (20 healthy participants and 60 patients with LE) will be enrolled. This will include 30 with Discoid Lupus Erythematosus/Subacute Cutaneous Lupus Erythematosus (DLE/SCLE) without Systemic Lupus Erythematosus (SLE), and 30 with DLE/SCLE with SLE. All patients with LE will continue to be managed by their personal physicians per their standard-of-care. Study participants will undergo interventional procedures that include collection of urine, blood samples and skin biopsy. There will be a single sample collection timepoint for healthy participants and two sample collection timepoints for LE patients, separated by approximately 12 weeks. A blood sample for genomic analysis will be collected for research purposes from patients who provide consent and where local regulations permit. The data obtained in this study will be used in the evaluation of new therapies for lupus and may help in developing new treatments. Safety evaluations will include assessment of adverse events, clinical laboratory tests, vital signs, and physical examinations. The total duration of study participation will be approximately 11 days for healthy participants and 95 days for patients with LE.
The superiority of drug-coated balloon (DCB) in treating small vessels, branching lesions, and high-risk bleeding lesions in coronary heart disease patients has been confirmed. However, its safety and efficacy in large vessels are still unclear. We aimed to investigate whether the efficacy of DCB in large vessels is not inferior to that of drug-eluting stent (DES). From November 2019 to April 2022, a total of 88 patients in our hospital who underwent coronary angiography for the first time and decided to receive DCB or DES treatment were selected. Indicators including late lumen loss (LLL), major adverse cardiovascular event (MACE) rate, major bleeding and all-cause mortality were evaluated at 9 months and 1-year post percutaneous coronary intervention (PCI) therapy. The primary endpoint of 9-month LLL was -0.07 in the DCB group and 0.19 mm in the DES group (p value<0.001). 1-year cumulative MACE rates were similar in the DCB and DES groups (3.03% vs. 7.23%, P=0.519), TLR rates were similar (3.03% vs. 7.23%, P=0.519), Major bleeding was similar (3.03% vs. 5.45%, P=0.580), and 1 case of Cardiac death in DES group. For LLL, the DCB-only strategy was non-inferior to DES in treating de novo large lesions in the coronary arteries. Furthermore, the efficacy of DCB was comparable to DES at 1 year of follow-up for secondary clinical endpoints.
Electrodes will be placed as they are in the Transcutaneous Spinal Cord Stimulation condition. Stimulation will be applied at subject's maximum intensity for 30 seconds and then discontinued.
CR was developed by Dr. Bowie (PI). Approximately 60% of CR sessions are spent on cognitive training activities, 20% on developing, monitoring, and flexibly adjusting problem-solving strategies, and 20% on transfer activities. Transfer includes discussing and role-playing how cognitive skills and strategies are applied in everyday life and teaches potential compensatory strategies for overcoming cognitive challenges. Targeted cognitive domains are processing speed, attention, memory, and executive functions, which are all commonly impaired in psychosis. The manual includes 1.5-hour sessions and uses Brain Training Pro and will be offered over an 8-week period. Zoom Health will be used for group transfer activities.
Methods and systems for estimating costs of perinatological or neonatological care are provided. An example system comprises a communication module for receiving historical perinatal data and beneficiary perinatal data. The system also includes a classification module to determine whether the historical perinatal data has met predetermined criteria. Based on the determination, the classification module selectively analyzes the historical perinatal data and the beneficiary perinatal data and attributes a beneficiary to at least one perinatal care episode based on the analysis. A scoring module of the system ascertains variables for calculation of a risk score associated with the perinatal care episode, determines coefficients corresponding to the variables, calculates the risk score for the beneficiary based on the coefficients, and assigns the beneficiary a financial risk tier based on the risk score for the perinatal care episode. The system may also include a payment calculation module and a virtual interface module.
Irregular vaginal bleeding or spotting may occur while you are taking the pills. Irregular bleeding may vary from slight staining between menstrual periods to breakthrough bleeding which is a flow much like a regular period. Irregular bleeding occurs most often during the first few months of oral contraceptive use, but may also occur after you have been taking the pill for some time. Such bleeding may be temporary and usually does not indicate any serious problems. It is important to continue taking your pills on schedule. If the bleeding occurs in more than one cycle or lasts for more than a few days, talk to your doctor or health care provider.
Patients receive placebo IV on day 1, etoposide IV on days 1-3 of courses 1-6, carboplatin IV on day 2 of courses 1-6, and ifosfamide IV on day 1-3 of courses 1-6. Placebo in combination with ICE chemotherapy repeats every 21 days for 6 courses.